We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb PR Newswire JERUSALEM, July 23, 2024 Scinai...
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model PR Newswire JERUSALEM, July 15, 2024 JERUSALEM, July 15, 2024 /PRNewswire/...
Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity PR Newswire JERUSALEM...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | FS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
